A pilot randomized trial comparing CD34-selected versus unmanipulated hemopoietic stem cell transplantation for severe, refractory rheumatoid arthritis

Arthritis and Rheumatism

Volumn 46, Issue 9, 2002, Pages 2301-2309

  Moore, John ^a   Brooks, Peter ^b   Milliken, Sam ^a   Biggs, Jim ^a   Ma, David ^a   Handel, Malcolm ^a   Cannell, Paul ^c   Will, Rob ^c   Rule, Simon ^d   Joske, David ^d   Langlands, Bob ^d   Taylor, Kerry ^e   O'Callaghan, Joe ^e   Szer, Jeff ^f   Wicks, Ian ^f   McColl, Geoff ^f   Passeullo, Frances ^g   Snowden, John ^h  

^a ST VINCENT S HOSPITAL   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c ROYAL PERTH HOSPITAL   (Australia)

^d SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^e MATER HOSPITAL   (Australia)

^f ROYAL MELBOURNE HOSPITAL   (Australia)

^g Amgen Australia   (Australia)

^h LEICESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; MESNA; METHOTREXATE; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RHEUMATOID FACTOR;

ADULT; ARTICLE; CELL SELECTION; CELL SEPARATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; FOLLOW UP; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LYMPHOCYTE DEPLETION; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; T LYMPHOCYTE; TOXICITY; TREATMENT FAILURE; TREATMENT OUTCOME;

ANTIGENS, CD34; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CYCLOPHOSPHAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEASIBILITY STUDIES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; IMMUNOSUPPRESSIVE AGENTS; METHOTREXATE; PILOT PROJECTS; RECURRENCE; RETREATMENT; RHEUMATOID FACTOR; SAFETY; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 0036743992     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.10495     Document Type: Article

References (19)

1. Pincus T, Callahan LF. What is the natural history of rheumatoid arthritis? Rheum Dis Clin North Am 1993;19:123-51.
2. Van Bekkum DW. New opportunities for the treatment of severe autoimmune diseases: bone marrow transplantation. Clin Immunol Immunopathol 1998;89:1-10.
3. Snowden JA, Brooks PM, Biggs JC. Haemopoietic stem cell transplantation for autoimmune diseases. Br J Haematol 1997;99:9-22.
4. Tyndall A, Fassas A, Passweg J, Ruiz de Elvira C, Attal M, Brooks P, et al. Autologous haematopoietic stem cell transplants for autoimmune disease: feasibility and transplant-related mortality. Bone Marrow Transplant 1999;24:729-34.
5. Euler HH, Marmont AM, Bacigalupo A, Fastenrath S, Dreger P, Hoffknecht M, et al. Early recurrence or persistence of autoimmune diseases after unmanipulated autologous stem cell transplantation. Blood 1996;88:3621-5.
6. Tyndall A, Gratwohl A. Blood and marrow stem cell transplants in auto-immune disease: a consensus report written on behalf of the European League against Rheumatism (EULAR) and the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant 1997;19:643-5.
7. Fox DA. The role of T cells in the immunopathogenesis of rheumatoid arthritis: new perspectives. Arthritis Rheum 1997;40:598-609.
8. Snowden JA, Biggs JC, Milliken ST, Fuller A, Brooks PM. A phase I/II dose escalation study of intensified cyclophosphamide and autologous blood stem cell rescue in severe, active rheumatoid arthritis. Arthritis Rheum 1999;42:2286-92.
9. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
10. Fries JF, Spitz PW, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum 1980;23:137-45.
11. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-35.
12. Snowden JA, Biggs JC, Milliken ST, Fuller A, Staniforth D, Passuello F, et al. A randomised, blinded, placebo-controlled, dose escalation study of the tolerability and efficacy of filgrastim for haemopoietic stem cell mobilisation in patients with severe active rheumatoid arthritis. Bone Marrow Transplant 1998;22:1035-41.
13. Burt RK, Georganas C, Schroeder J, Traynor A, Stefka J, Schuening F, et al. Autologous hematopoietic stem cell transplantation in refractory rheumatoid arthritis: sustained response in two of four patients. Arthritis Rheum 1999;42:2281-5.
14. Verburg RJ, Kruize AA, van den Hoogen FHJ, Fibbe WE, Petersen EJ, Preijers F, et al. High-dose chemotherapy and autologous hematopoietic stem cell transplantation in patients with rheumatoid arthritis: results of an open study to assess feasibility, safety, and efficacy. Arthritis Rheum 2001;44:754-60.
15. Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999;340:253-9.
16. Maini R, St.Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Lancet 1999;354:1932-9.
17. Holmberg LA, Boeckh M, Hooper H, Leisenring W, Rowley S, Heimfeld S, et al. Increased incidence of cytomegalovirus disease after autologous CD34-selected peripheral blood stem cell transplantation. Blood 1999;94:4029-35.
18. Van der Lubbe PA, Dijkmans BAC, Markusse HM, Nässander U, Breedveld FC. A randomized, double-blind, placebo-controlled study of CD4 monoclonal antibody therapy in early rheumatoid arthritis. Arthritis Rheum 1995;38:1097-106.
19. Edwards JCW, Cambridge G. Rheumatoid arthritis: the predictable effect of small immune complexes in which antibody is also antigen. Br J Rheumatol 1998;37:126-30.